Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations

British Journal of Cancer

Volumn 108, Issue 2, 2013, Pages 429-437

  Pinato, D J ^a,b   Ramachandran, R ^a   Toussi, S T K ^a   Vergine, M ^a   Ngo, N ^a   Sharma, R ^a   Lloyd, T ^a   Meeran, K ^a   Palazzo, F ^a   Martin, N ^a   Khoo, B ^c   Dina, R ^b   Tan, T M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Carbonic anhydrase IX; Hif 1 ; mTOR; Paraganglioma; Phaeochromocytoma; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN A;

ADULT; ARTICLE; DEMOGRAPHY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PARAGANGLIOMA; PHENOTYPE; PHEOCHROMOCYTOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; UPREGULATION;

ADRENAL GLAND NEOPLASMS; ADULT; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CELL HYPOXIA; FEMALE; GERM-LINE MUTATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM METASTASIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROTO-ONCOGENE PROTEINS C-AKT; TISSUE ARRAY ANALYSIS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84873569493     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.538     Document Type: Article

References (49)

1. Agarwal A, Mehrotra PK, Jain M, Gupta SK, Mishra A, Chand G, Agarwal G, Verma AK, Mishra SK, Singh Ü(2010) Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): Can they predict malignancy? World J Surg 34(12): 3022-3028.
2. Ahlman H (2006) Malignant pheochromocytoma: State of the field with future projections. Ann NY Acad Sci 1073: 449-464. (Pubitemid 44912040)
3. Allibhai Z, Rodrigues G, Brecevic E, Neumann HP, Winquist E (2004) Malignant pheochromocytoma associated with germline mutation of the SDHB gene. J Urol 172(4 Pt 1): 1409-1410. (Pubitemid 39249731)
4. Blank A, Schmitt AM, Korpershoek E, van Nederveen F, Rudolph T, Weber N, Strebel RT, de Krijger R, Komminoth P, Perren A (2010) SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling. Endocr Relat Cancer 17(4): 919-928.
5. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF (2002) CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: Identification of an endocrine-sensitive subgroup. Clin Cancer Resh 8(7): 2233-2239. (Pubitemid 34753595)
6. Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K (2006) High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: Implications for genetic testing. J Clin Endocrinol Metab 91(11): 4505-4509. (Pubitemid 44833431)
7. Brukamp E, Haase VH (2006) Von Hippel-LindaüDisease, Phaeochromocytoma and Hypertension. In Advanced therapy in hypertension and vascular disease, Mohler ER, Townsend RR (eds). pp 660-668. B.C. Decker: Hamilton, Ontario, Canada.
8. Covello KL, Kehler J, YüH, Gordan JD, Arsham AM, HüCJ, Labosky PA, Simon MC, Keith B (2006) HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 20(5): 557-570. (Pubitemid 43345322)
9. Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL, Sanso G, Powers JF, Tischler AS, Hodin R, Heitritter S, Moore F, Dluhy R, Sosa JA, Ocal IT, Benn DE, Marsh DJ, Robinson BG, Schneider K, Garber J, Arum SM, Korbonits M, Grossman A, Pigny P, Toledo SP, Nose V, Li C, Stiles CD (2005) A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 1(1): 72-80.
10. DeLellis RA, Lloyd RV, Heitz P, Eng C (2004) Pathology and Genetics of Tumours of Endocrine Organs. IARC: Lyon.
11. Dhillon T, Mauri FA, Bellezza G, Cagini L, Barbareschi M, North BV, Seckl MJ (2010) Overexpression of the mammalian target of rapamycin: A novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol 5(3): 314-319.
12. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB (2009) Novel and evolving therapies in the treatment of malignant phaeochromocytoma: Experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 41(9): 697-702.
13. Eisenhofer G, Tischler AS, de Krijger RR (2012) Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: From routine laboratory methods to disease stratification. Endocr Pathol 23(1): 4-14.
14. Fassnacht M, Weismann D, Ebert S, Adam P, Zink M, Beuschlein F, Hahner S, Allolio B (2005) AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors. J Clin Endocrinol Metab 90(7): 4366-4370. (Pubitemid 41058221)
15. Favier J, Briere JJ, Burnichon N, Riviere J, Vescovo L, Benit P, Giscos-Douriez I, De Reynies A, Bertherat J, Badoual C, Tissier F, Amar L, Libe R, Plouin PF, Jeunemaitre X, Rustin P, Gimenez-Roqueplo AP (2009) The Warburg effect is genetically determined in inherited pheochromocytomas. PloS one 4(9): E7094.
16. Favier J, Plouin PF, Corvol P, Gasc JM (2002) Angiogenesis and vascular architecture in pheochromocytomas: Distinctive traits in malignant tumors. Am J Pathol 161(4): 1235-1246.
17. Gao B, Kong F, XüZ (2008) Development of differential diagnosis for benign and malignant pheochromocytomas. Int J Urol 15(9): 771-777.
18. Giatromanolaki A, Harris AL (2001) Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. Anticancer Res 21(6B): 4317-4324. (Pubitemid 34245369)
19. Gill AJ, Benn DE, ChoüA, Clarkson A, Muljono A, Meyer-Rochow GY, Richardson AL, SidhüSB, Robinson BG, Clifton-Bligh RJ (2010) Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol 41(6): 805-814.
20. Gimenez-Roqueplo AP, Burnichon N, Amar L, Favier J, Jeunemaitre X, Plouin PF (2008) Recent advances in the genetics of phaeochromocytoma and functional paraganglioma. Clin Exp Pharmacol Physiol 35(4): 376-379. (Pubitemid 351326766)
21. Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER, Plouin PF (2006) Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) 65(6): 699-705. (Pubitemid 44773690)
22. Gimm O, DeMicco C, Perren A, Giammarile F, Walz MK, Brunaud L (2012) Malignant pheochromocytomas and paragangliomas: A diagnostic challenge. Langenbeck's Arch Surg/ Deutsche Gesellschaft fur Chirurgie 397(2): 155-177.
23. Gottlieb E, Tomlinson IP (2005) Mitochondrial tumour suppressors: A genetic and biochemical update. Nat Rev Cancer 5(11): 857-866. (Pubitemid 41746030)
24. Harari A, Inabnet 3rd WB (2011) Malignant pheochromocytoma: A review. Am J Surg 201(5): 700-708.
25. Kaluz S, Kaluzova M, Liao SY, Lerman M, Stanbridge EJ (2009) Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta 1795(2): 162-172.
26. Kim JJ, Rini BI, Hansel DE (2010) Von Hippel-Lindaüsyndrome. Adv Exp Med Biol 685: 228-249.
27. Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y (2005) Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: A clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16(1): 23-32. (Pubitemid 41278311)
28. Koch CA, Mauro D, Walther MM, Linehan WM, Vortmeyer AO, Jaffe R, Pacak K, Chrousos GP, Zhuang Z, Lubensky IA (2002) Pheochromocytoma in von Hippel-Lindaüdisease: Distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol 13(1): 17-27. (Pubitemid 34665112)
29. Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, Badoual C, Gadessaud N, Venisse A, Bayley JP, van Dooren MF, de Herder WW, Tissier F, Plouin PF, van Nederveen FH, Dinjens WN, Gimenez-Roqueplo AP, de Krijger RR (2011) SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 96(9): E1472-E1476.
30. Ladroue C, Carcenac R, Leporrier M, Gad S, Le Hello C, Galateau-Salle F, Feunteun J, Pouyssegur J, Richard S, Gardie B (2008) PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 359(25): 2685-2692.
31. Lavecchia MJ, Diez RP, Colinas PA (2011) A combined theoretical and spectroscopic study of 4,6-di-O-acetyl-2,3-dideoxy-D-erythro-hex-2-enopyranosyl sulfamide: A novel glycosyl carbonic anhydrase IX inhibitor. Carbohydr Res 346(3): 442-448.
32. Loboda A, Jozkowicz A, Dulak J (2010) HIF-1 and HIF-2 transcription factors-similar but not identical. Mol Cells 29(5): 435-442.
33. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10(6): 594-601. (Pubitemid 38796850)
34. Manger WM, Eisenhofer G (2004) Pheochromocytoma: Diagnosis and management update. Curr Hypertens Rep 6(6): 477-484. (Pubitemid 39600104)
35. Middeke M, Hoffmann S, Hassan I, Wunderlich A, Hofbauer LC, Zielke A (2002) In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor. Exp Clin Endocrinol Diab 110(8): 386-392. (Pubitemid 36041889)
36. Nolting S, Grossman AB (2012) Signaling pathways in pheochromocytomas and paragangliomas: Prospects for future therapies. Endocr Pathol 23(1): 21-33.
37. Petri BJ, van Eijck CH, de Herder WW, Wagner A, de Krijger RR (2009) Phaeochromocytomas and sympathetic paragangliomas. Br J Surg 96(12): 1381-1392.
38. Pollard PJ, El-Bahrawy M, Poulsom R, Elia G, Killick P, Kelly G, Hunt T, Jeffery R, Seedhar P, Barwell J, Latif F, Gleeson MJ, Hodgson SV, Stamp GW, Tomlinson IP, Maher ER (2006) Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 91(11): 4593-4598. (Pubitemid 44833443)
39. Reisch N, Peczkowska M, Januszewicz A, Neumann HP (2006) Pheochromocytoma: Presentation, diagnosis and treatment. J Hypertens 24(12): 2331-2339. (Pubitemid 44684675)
40. Salmenkivi K, Haglund C, Ristimaki A, Arola J, Heikkila P (2001) Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab 86(11): 5615-5619. (Pubitemid 33070296)
41. Salmenkivi K, Heikkila P, LiüJ, Haglund C, Arola J (2003) VEGF in 105 pheochromocytomas: Enhanced expression correlates with malignant outcome. APMIS 111(4): 458-464. (Pubitemid 36735003)
42. Semenza GL (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12(19-20): 853-859. (Pubitemid 47554628)
43. Srirangalingam U, Walker L, Khoo B, MacDonald F, Gardner D, Wilkin TJ, Skelly RH, George E, Spooner D, Monson JP, Grossman AB, Akker SA, Pollard PJ, Plowman N, Avril N, Berney DM, Burrin JM, Reznek RH, Kumar VK, Maher ER, Chew SL (2008) Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol (Oxf) 69(4): 587-596.
44. Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA (2008) Prognostic indicators of malignancy in adrenal pheochromocytomas: Clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 143(6): 759-768.
45. Swietach P, Vaughan-Jones RD, Harris AL (2007) Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 26(2): 299-310. (Pubitemid 47101667)
46. Takekoshi K, Isobe K, Yashiro T, Hara H, Ishii K, Kawakami Y, Nakai T, Okuda Y (2004) Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas. Life Sci 74(7): 863-871. (Pubitemid 37501135)
47. Thompson LD (2002) Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26(5): 551-566. (Pubitemid 34438716)
48. Wagner PD, Srivastava S (2012) New paradigms in translational science research in cancer biomarkers. Transl Res 159(4): 343-353.
49. Zatovicova M, Jelenska L, Hulikova A, Csaderova L, Ditte Z, Ditte P, Goliasova T, Pastorek J, Pastorekova S (2010) Carbonic anhydrase IX as an anticancer therapy target: Preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des 16(29): 3255-3263.